| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TACSTD2 |
| Uniprot No | P09758 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-323aa |
| 氨基酸序列 | HTAAQDNCTCPTNKMTVCSPDGPGGRCQCRALGSGMAVDCSTLTSKCLLL KARMSAPKNARTLVRPSEHALVDNDGLYDPDCDPEGRFKARQCNQTSVCW CVNSVGVRRTDKGDLSLRCDELVRTHHILIDLRHRPTAGAFNHSDLDAEL RRLFRERYRLHPKFVAAVHYEQPTIQIELRQNTSQKAAGDVDIGDAAYYF ERDIKGESLFQGRGGLDLRVRGEPLQVERTLIYYLDEIPPKFSMKRLTAG LIAVIVVVVVALVAGMAVLVITNRRKSGKYKKVEIKELGELRKEPSL |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TACSTD2(TROP2)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant expression and functional characterization of TACSTD2 in epithelial cancer progression"*
**作者**：Li, X., et al.
**摘要**：研究通过大肠杆菌系统成功表达重组TACSTD2蛋白，并验证其在体外促进乳腺癌细胞迁移和侵袭的作用，揭示其通过激活ERK信号通路参与肿瘤转移。
---
2. **文献名称**：*"Structural insights into TROP2 extracellular domain by recombinant protein crystallization"*
**作者**：Guerra, E., et al.
**摘要**：利用昆虫细胞表达系统获得高纯度TACSTD2胞外域重组蛋白，通过X射线晶体学解析其三维结构，为靶向TROP2的抗体药物设计提供结构基础。
---
3. **文献名称**：*"TACSTD2 recombinant protein-based vaccine induces anti-tumor immunity in colorectal models"*
**作者**：Zhao, R., et al.
**摘要**：开发基于重组TACSTD2蛋白的肿瘤疫苗，证明其能激活特异性T细胞应答并显著抑制结直肠癌小鼠模型的肿瘤生长，提示其免疫治疗潜力。
---
注：上述文献为模拟示例，实际引用需以具体数据库(如PubMed、Web of Science)检索结果为准。
**Background of TACSTD2 Recombinant Protein**
TACSTD2 (tumor-associated calcium signal transducer 2), also known as Trop-2. is a transmembrane glycoprotein encoded by the *TACSTD2* gene. It belongs to the epithelial cell adhesion molecule (EpCAM) family and plays critical roles in cell signaling, adhesion, and proliferation. Structurally, TACSTD2 contains an extracellular domain with thyroglobulin-type repeats, a transmembrane region, and a short cytoplasmic tail with a phosphorylation site that modulates intracellular signaling pathways.
TACSTD2 is overexpressed in numerous epithelial cancers, including breast, lung, pancreatic, and colorectal cancers, where it promotes tumor growth, metastasis, and resistance to therapy. Its dysregulation is linked to activation of pathways like MAPK/ERK and PI3K/AKT, driving oncogenic progression. In contrast, normal tissues exhibit low or restricted expression, making TACSTD2 a promising therapeutic target and diagnostic biomarker.
Recombinant TACSTD2 protein is engineered using expression systems (e.g., HEK293 or *E. coli*) to produce purified, biologically active forms of the protein. This recombinant protein typically includes functional extracellular domains, enabling studies on ligand-receptor interactions, antibody development, and immune response modulation. It is widely used in *in vitro* assays, structural studies, and preclinical evaluations of targeted therapies, such as antibody-drug conjugates (ADCs) like sacituzumab govitecan, which received FDA approval for metastatic triple-negative breast cancer.
Research on TACSTD2 recombinant protein also explores its role in regenerative medicine and tissue repair, as it may influence epithelial cell behavior. However, challenges remain in understanding its dual roles in cancer promotion and normal tissue homeostasis, necessitating further mechanistic studies. Overall, TACSTD2 recombinant protein serves as a vital tool for advancing cancer therapeutics and understanding cell signaling dynamics.
×
